Atrial fibrillation is associated with an increased risk of myocardial infarction: Insights from a meta-analysis

Atherosclerosis

Volumn 254, Issue , 2016, Pages 1-7

  Guo, Xue Yuan ^a   Li, Na ^b   Du, Xin ^a   Bai, Rong ^a   Yu, Rong Hui ^a   Long, De Yong ^a   Tang, Ri Bo ^a   Sang, Cai Hua ^a   Jiang, Chen Xi ^a   Ning, Man ^a   Li, Song Nan ^a   Liu, Nian ^a   Dong, Jian Zeng ^a   Ma, Chang Sheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Meta analysis; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMATIC REVIEW; AGED; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPLICATION; FEMALE; INFORMATION PROCESSING; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COMORBIDITY; DATA COLLECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDIES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84988644303     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.09.011     Document Type: Article

References (40)

1. [1] Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:18 (2001), 2370–2375.
2. [2] Miyasaka, Y., Barnes, M.E., Gersh, B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114:2 (2006), 119–125.
3. [3] Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125:1 (2012), e2–e220.
4. [4] Miyasaka, Y., Barnes, M.E., Bailey, K.R., et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J. Am. Coll. Cardiol. 49:9 (2007), 986–992.
5. [5] Conen, D., Chae, C.U., Glynn, R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 305:20 (2011), 2080–2087.
6. [6] O'Neal, W.T., Sangal, K., Zhang, Z.M., et al. Atrial fibrillation and incident myocardial infarction in the elderly. Clin. Cardiol. 37:12 (2014), 750–755.
7. [7] Chao, T.F., Huang, Y.C., Liu, C.J., et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 11:11 (2014), 1941–1947.
8. [8] Soliman, E.Z., Safford, M.M., Muntner, P., et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 174:1 (2014), 107–114.
9. [9] Soliman, E.Z., Lopez, F., O'Neal, W.T., et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the atherosclerosis risk in communities (ARIC) study. Circulation 131:21 (2015), 1843–1850.
10. [10] Du, X., Ninomiya, T., de Galan, B., et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur. Heart J. 30:9 (2009), 1128–1135.
11. [11] Aguilar, E., Garcia-Diaz, A.M., Sanchez Munoz-Torrero, J.F., et al. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. Thromb. Res. 130:3 (2012), 390–395.
12. [12] Verdecchia, P., Dagenais, G., Healey, J., et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J. Hypertens. 30:5 (2012), 1004–1014.
13. [13] Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.
14. [14] Wells, G.A., Shea, B., O'Connell, D., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed on March 8, 2016.
15. [15] Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
16. [16] Stewart, S., Hart, C.L., Hole, D.J., et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113:5 (2002), 359–364.
17. [17] Wachtell, K., Hornestam, B., Lehto, M., et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 45:5 (2005), 705–711.
18. [18] Wachtell, K., Lehto, M., Gerdts, E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 45:5 (2005), 712–719.
19. [19] Andersson, T., Magnuson, A., Bryngelsson, I.L., et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int. J. Cardiol. 177:1 (2014), 91–99.
20. [20] Fatemi, O., Yuriditsky, E., Tsioufis, C., et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am. J. Cardiol. 114:8 (2014), 1217–1222.
21. [21] You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl (2012), 531S–575S e.
22. [22] Kolodgie, F.D., Virmani, R., Finn, A.V., et al. Embolic myocardial infarction as a consequence of atrial fibrillation: a prevailing disease of the future. Circulation 132:4 (2015), 223–226.
23. [23] Prizel, K.R., Hutchins, G.M., Bulkley, B.H., Coronary artery embolism and myocardial infarction. Ann. Intern Med. 88:2 (1978), 155–161.
24. [24] Shibata, T., Kawakami, S., Noguchi, T., et al. Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism. Circulation 132:4 (2015), 241–250.
25. [25] Benjamin, E.J., Levy, D., Vaziri, S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271:11 (1994), 840–844.
26. [26] Guo, Y., Lip, G.Y., Apostolakis, S., Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 60:22 (2012), 2263–2270.
27. [27] Marcus, G.M., Smith, L.M., Ordovas, K., et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 7:2 (2010), 149–154.
28. [28] Akar, J.G., Jeske, W., Wilber, D.J., Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J. Am. Coll. Cardiol. 51:18 (2008), 1790–1793.
29. [29] Lim, H.S., Willoughby, S.R., Schultz, C., et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J. Am. Coll. Cardiol. 61:8 (2013), 852–860.
30. [30] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of cardiology foundation/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 61:4 (2013), e78–140.
31. [31] Liao, J.K., Laufs, U., Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 89–118.
32. [32] Franzoni, F., Quinones-Galvan, A., Regoli, F., et al. A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90:2–3 (2003), 317–321.
33. [33] Niska, R., Han, B., Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J. Am. Board Fam. Med. 22:3 (2009), 299–306.
34. [34] Gorin, L., Fauchier, L., Nonin, E., et al. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140:4 (2011), 911–917.
35. [35] Yahagi, K., Davis, H.R., Arbustini, E., et al. Sex differences in coronary artery disease: pathological observations. Atherosclerosis 239:1 (2015), 260–267.
36. [36] Rothberg, M.B., Celestin, C., Fiore, L.D., et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern Med. 143:4 (2005), 241–250.
37. [37] Dukes, J.W., Marcus, G.M., Atrial fibrillation begets myocardial infarction. JAMA Intern Med. 174:1 (2014), 5–7.
38. [38] Verheugt, F.W., Granger, C.B., Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386:9990 (2015), 303–310.
39. [39] Skjoth, F., Larsen, T.B., Rasmussen, L.H., et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb. Haemost. 111:5 (2014), 981–988.
40. [40] Hohnloser, S.H., Lip, G.Y., Dabigatran and myocardial infarction. Chest 147:2 (2015), e70–71.